

Programme

Sunday September 1, 2024

13:30 **Registration**

16:00 **Opening Ceremony**

Dr Luc VAN HIJFTE (SYMERES, Nijmegen, The Netherlands)
Prof. Roberto DI SANTO (SAPIENZA UNIVERSITY OF ROME, Rome, Italy)

16:20 **Opening Lecture - Patient Testimonial**

Chair

Prof. Angela RUSSELL
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

16:50 **Musical Interlude**

17:00 **EFMC Awards Ceremony**

Dr Luc VAN HIJFTE
(SYMERES, Nijmegen, The Netherlands)

17:20 **NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
From Sea to Pharmacy: Marine Biology & Drug Development Adventures (AL001)**

Dr Laurent MEIJER
(PERHA PHARMACEUTICALS, Roscoff, France)

18:00 **GDCh - Klaus Grohe Prize Ceremony**

Prize Ceremony

18:10 **KLAUS GROHE PRIZE
Lightening the Burden: Illuminating Precision Influencers of Innate Electrophile Signaling for Functional Drug
Discovery (PR001)**

Prof. Yimon AYE
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

18:50 **Welcome Reception**

20:00 **End of the Day**

Programme

Monday September 2, 2024

08:00 Registration

08:30 **OPENING PLENARY LECTURE**
Photoredox and Organocatalysis in Medicinal Chemistry (PL001)

Prof. David MACMILLAN
(PRINCETON UNIVERSITY, Princeton, United States)

09:10 **UCB EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY**
Bringing Bump-and-Hole to Molecular Glues: the Development of Orthogonal Imid-Degron Pairs (AL002)

Prof. Stuart CONWAY
(UCLA, Los Angeles, United States)

09:50 Exhibition & Coffee

Session *Session 1 'Chemical Biology'*

Tackling "Difficult-to-Drug"-Targets with Chemical Biology Approaches

10:20 **Session Chair**

Dr Jacob BUSH
(GSK, Stevenage, United Kingdom)

10:25 **Next-Generation Covalent Drug Discovery (LE001)**

Dr Lyn H. JONES
(DANA FARBER CANCER INSTITUTE, Boston, MA, United States)

11:05 **Synthesis and Screening Large Libraries of Small Cyclic Peptides to Target Intracellular Protein-Protein Interactions (LE002)**

Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

11:25 **A Simple Method for Developing Lysine Targeted Covalent Protein Reagents (LE003)**

Dr Ronen GABIZON
(WEIZMANN INSTITUTE, Rehovot, Israel)

11:45 **A Chemical Proteomics Platform to Profile Cellular Target Engagement of Kinase Inhibitors Across >80% of the Kinome (LE004)**

Mr Joel RÜEGGER
(UNIVERSITY LEIDEN, Leiden, The Netherlands)

Session *Session 2 'Drug Discovery Projects'*

Drug Discovery Beyond the Rule of Five

10:20 **Session Chair**

Prof. Iwan DE ESCH
(VU AMSTERDAM, Amsterdam, The Netherlands)

10:25 **Design of Oral Drugs in the Beyond Rule of 5 Space - Knowns, Unknowns, Potential Breakthroughs (LE005)**

Prof. Jan KIHILBERG
(UPPSALA UNIVERSITY, Uppsala, Sweden)

11:05 **Physicochemical Attributes and ADME Optimization Challenges of Oral Bifunctional Degradable Molecules - (LE006)**

Dr Andy PIKE
(ASTRAZENECA, Cambridge, United Kingdom)

11:25 **Identification of TAK-756, a Potent and Selective TAK1 Inhibitor for the Treatment of Osteoarthritis Through Intra-Articular Administration (LE007)**

Dr Jean-Baptiste LANGLOIS
(NOVARTIS PHARMA, Basel, Switzerland)

11:45 **Self-Immolative Pleiotropic Prodrugs: an Innovative way to Treat Alzheimer's Disease? (LE008)**

Programme

Dr Valentin TRAVERS-LESAGE
(CERMN - UNIVERSITÉ CAEN NORMANDIE, Caen Cedex, France)

Session *Session 3 'Technologies'*

Novel Methodologies in Photo- and Electrochemistry

- 10:20 Session Chair**
Dr Lisa CANDISH
(BAYER, Wuppertal, Germany)
- 10:25 The Application of Photoredox Chemistry at GSK (LE009)**
Ms Gemma COOK
(GSK, Stevenage, United Kingdom)
- 11:05 Reductive Organic Electrosynthesis for Activation of Strong Chemical Bonds (LE010)**
Prof. Helena LUNDBERG
(KTH ROYAL INSTITUTE OF TECHNOLOGY, Stockholm, Sweden)
- 11:25 Automation in Medicinal Chemistry and New Enabling Methodologies at J&J (LE011)**
Dr José Enrique GÓMEZ
(JOHNSON & JOHNSON, Toledo, Spain)
- 11:45 Synthesis of Aryl-Fused Bicyclo[3.1.1]Heptanes (BCHepts) and Validation as Naphthyl Bioisosteres (LE012)**
Dr Pol HERNÁNDEZ-LLADÓ
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
- 12:05 Exhibition & Lunch**
Optional Company workshops

Session Flash Poster Session 1

FP01 to FP10

Opportunity for 10 young scientists to present a summary of their poster

Session Flash Poster Session 2

FP11 to FP20

Opportunity for 10 young scientists to present a summary of their poster

Session Flash Poster Session 3

FP21 to FP30

Opportunity for 10 young scientists to present a summary of their poster

Session *Session 4 'Chemical Biology'*

Targeting RNA and RNA-Regulatory Proteins

- 13:45 Session Chair**
Dr Matthew FYFE
(STORM THERAPEUTICS LIMITED, Cambridge, United Kingdom)
- 13:50 Visualizing and Decoding mRNA Biology to Advance Understanding of Diseases and Treatments (LE013)**
Dr Iris ALROY
(ANIMA BIOTECH INC., Ramat Gan, Israel)
- 14:30 Hit Discovery for Riboswitches as Targets for Antibiotics (LE014)**
Prof. Ruth BRENK
(UNIVERSITY OF BERGEN, Bergen, Norway)
- 14:50 Lessons Learned from Structure-Based RNA-Ligand Design (LE015)**
Dr Christian KERSTEN
(JOHANNES GUTENBERG UNIVERSITY, Mainz, Germany)
- 15:10 Structure-Based Design of a Potent and Selective YTHDC1 Ligand (LE016)**
Dr Frantisek ZALESK
(UZH ZURICH, Zurich, Switzerland)

Programme

Session *Session 5 'Drug Discovery Projects'*

Early Integration of Translational Strategies into Discovery Projects

- 13:45 Session Chair**
Dr Antonia F. STEPAN
(F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland)
- 13:50 Translating Small Molecules that Impact Protein Homeostasis (LE017)**
Dr Patrick Robert VERHOEST
(PFIZER GLOBAL RESEARCH, Groton, United States)
- 14:30 Profiling and Mode of Action Deconvolution of Early Hit and Lead Molecules by an Interdisciplinary High-Throughput PhenOMICS Platform (LE018)**
Dr Sebastian ESSIG
(BAYER AG, Wuppertal, Germany)
- 14:50 Translational Biomarker Strategy for Development of MK-4334, a Novel Positive Allosteric Modulator of the $\alpha 7$ nAChR (LE019)**
Dr Ian BELL
(MSD, West Point, United States)
- 15:10 Discovery of ASTX295: a Bone-Marrow Sparing MDM2 Antagonist. From Concept to Clinic (LE020)**
Dr Gianni CHESSARI
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Session *Session 6 'Technologies'*

DNA-Encoded Libraries / ACSMEDI Session

- 13:45 Session Chair**
Dr Amanda GARNER
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)
- 13:50 DNA Encoded Technologies for Hit-finding in Academia and Industry (LE021)**
Dr Alex SATZ
(WUXI APPTTEC, Basel, Switzerland)
- 14:30 Recent Advances in DNA-Encoded Library Technologies at GSK (LE022)**
Dr Lisa MARCAURELLE
(GSK, Cambridge, United States)
- 14:50 Using DEL for Targeted Protein Modulation (LE023)**
Dr Gwenn HANSEN
(NURIX, INC., San Francisco, United States)
- 15:10 Macrocyclic MCL-1 Inhibitors: an Efficient Combination of DNA-Encoded Library Screening, Parallel Macrocyclic Library Synthesis, Conformational Analysis and Structure-Based Design (LE024)**
Dr Koen HEKKING
(SYMERES, Nijmegen, The Netherlands)
- 15:30 Exhibition & Coffee**

Session *Session 7*

First Time Disclosure - Part I

- Session Chair**
Dr Karin BRINER
(GENENTECH, South San Francisco, United States)
- 16:00 Discovery and Development of a First in Class MKK-4 Inhibitor to Increase Liver Regeneration First Disclosure of the Clinical Candidate HRX-215 (LE025)**
Prof. Stefan LAUFER
(UNIVERSITY OF TüBINGEN, Tübingen, Germany)
- 16:30 Discovery of BAY 2413555, First Highly Selective Positive Allosteric Modulator of the M2 Receptor to Restore Autonomic Balance in Heart Failure Patients (LE026)**
Dr Alexandros VAKALOPOULOS
(BAYER, Wuppertal, Germany)

Programme

- 17:00

Discovery of NVP-EVS459, a Low Molecular Weight Folate Receptor Targeting Radioconjugate for the Treatment of Folate Receptor Positive Cancers with First-In-Class Potential (LE027)

Dr Philipp HOLZER
(NOVARTIS PHARMA AG, Basel, Switzerland)
- 17:30

Poster Session 1 & Networking
- 19:00

End of the Day

Programme

Tuesday September 3, 2024

- 08:30 PROUS INSTITUTE - OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY Title to be Announced (AL003)**
Prof. Véronique GOUVERNEUR
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)
- 09:10 New Directions in Drug Discovery: Expanding Exploration of Chemical Space (PL002)**
Dr Emma PARMEE
(JANSSEN RESEARCH & DEVELOPMENT, Spring House, United States)
- 09:50 Exhibition & Coffee**

Session Session 8 'Chemical Biology'

Chemically Induced Proximity Approaches for Therapeutic Intervention

- 10:20 Session Chair**
Dr Gregory HOLLINGWORTH
(NOVARTIS PHARMA AG, Basel, Switzerland)
- 10:25 Title to be Announced (LE028)**
Dr Bin YANG
(KYMERA THERAPEUTICS, INC., Watertown, United States)
- 11:05 A Quantitative Understanding of PPI Stabilization; or How to Identify Chemical Glues (LE029)**
Prof. Luc BRUNSVELD
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)
- 11:25 Teaching Cereblon new Tricks: Design of Novel Molecular Glue Degraders (LE030)**
Dr Magnus WALTER
(MONTE ROSA THERAPEUTICS, Basel, Switzerland)
- 11:45 Rewiring Transcription with Bivalent Gain-of-Function Molecules (LE031)**
Dr Roman SAROTT
(STANFORD UNIVERSITY, Menlo Park, United States)

Session Session 9 'Drug Discovery Projects'

Trends in Peptide Drug Discovery

- 10:20 Session Chair**
Dr Gilles GUICHARD
(UNIVERSITY OF BORDEAUX, CBMN, Bordeaux, France)
- 10:25 Applications of Cyclotides as Stable Peptide Scaffolds for Drug Discovery (LE032)**
Prof. David CRAIK
(UNIVERSITY OF QUEENSLAND, Brisbane, Australia)
- 11:05 Trends in Peptide Drug Discovery for Diabetes and Obesity (LE033)**
Dr Søren ØSTERGAARD
(NOVO NORDISK, København, Denmark)
- 11:25 From Reversible to Irreversible Peptide Inhibitors of the TRF2^{TRFH} Recruiting Functions: a Strategy to Induce Replication Stress in Cancer Cells (LE034)**
Prof. Sandro COSCONATI
(UNIVERSITY OF CAMPANIA LUIGI VANVITELLI, Caserta, Italy)
- 11:45 Evolution Towards Clinical Candidate MK-0616: Next Generation Oral Tricyclic Peptide PCSK9 Inhibitors for LDL-Lowering and Coronary Heart Diseases (LE035)**
Dr Danila BRANCA
(IRBM SPA, Pomezia, Italy)

Session Session 10 'Technologies'

Computational Chemistry and Computational Biology in Drug Discovery

Programme

10:20 Session Chair

Dr Marco DE VIVO
(ITALIAN INSTITUTE OF TECHNOLOGY, Genova, Italy)

10:25 Computational Microscopy of Viral Targets for Drug & Immunogen Design (LE036)

Prof. Rommie AMARO
(UNIVERSITY OF CALIFORNIA, San Diego, United States)

11:05 Deciphering the Molecular Mechanism of pre-mRNA Splicing in Health and Disease (LE037)

Prof. Alessandra MAGISTRATO
(CNR-IOM, Trieste, Italy)

11:25 Accurate Estimation of Binding Free Energies on Challenging Protein-Ligand Complexes (LE038)

Mr Maurice KARRENBROCK
(UNIVERSITY OF GENEVA, Genève, Switzerland)

11:45 Discovery of HRO761, a First-In-Class Allosteric WRN Inhibitor by Property-Based Design Using AB Initio Conformational Analysis (LE039)

Dr Henrik MÖBITZ
(NOVARTIS, Basel, Switzerland)

12:05 Exhibition & Lunch Optional Company workshops

Session Flash Poster Session 4

FP31 to FP40

Opportunity for 10 young scientists to present a summary of their poster

Session Flash Poster Session 5

FP41 to FP50

Opportunity for 10 young scientists to present a summary of their poster

Session Flash Poster Session 6

FP51 to FP60

Opportunity for 10 young scientists to present a summary of their poster

Session Session 11 'Chemical Biology'

Small Molecule Treatments for Protein Misfolding Diseases

13:45 Session Chair

Dr Mark BUNNAGE
(VERTEX PHARMACEUTICALS, Boston, United States)

13:50 Discovery of CFTR Modulators for the Treatment of Cystic Fibrosis (LE040)

Dr Sabine HADIDA
(VERTEX PHARMACEUTICALS, San Diego, United States)

14:30 Discovery of Small Molecule Pharmacological Chaperones Targeting Intrinsically Disordered Proteins as an Anti-Aggregation Therapeutic Approach for Protein Misfolding Diseases (LE041)

Dr Gergely TOTH
(CANTABIO PHARMACEUTICALS INC., Palo Alto, United States)

14:50 Development of Novel Microbiota-Inspired Compounds as Drug Candidates for NPM1-Mutated Acute Myeloid Leukemia (LE042)

Ms Anabel SANCHEZ MERINO
(UNIVERSIDAD COMPLUTENSE DE MADRID, Madrid, Spain)

15:10 A Spotlight on Innovative Small Molecules to Tackle Prion Diseases (LE043)

Prof. Maria Letizia BARRECA
(UNIVERSITY OF PERUGIA, Perugia, Italy)

Programme

Session Session 12 'Drug Discovery Projects'

Addressing Unmet Needs on Emerging and Re-Emerging Infectious Diseases

- 13:45 Session Chair**
Dr Vincenzo SUMMA
(UNIVERSITY OF NAPLES FEDERICO II, Naples, Italy)
- 13:50 Strategies for Addressing Unmet Needs in Drug-resistant Tropical Diseases (LE044)**
Prof. Kelly CHIBALE
(UNIVERSITY OF CAPE TOWN, Cape Town, South Africa)
- 14:30 Discovery of JNJ-1802, a First-in-Class, Pan Serotype Dengue Antiviral Small Molecule. From Hit to Clinical Candidate (LE045)**
Dr Tim JONCKERS
(JANSSEN, Beerse, Belgium)
- 14:50 Structure-Guided Design and Synthesis of a Pyridazinone Series of Trypanosoma Cruzi Proteasome Inhibitors (LE046)**
Dr Pilar MANZANO-CHINCHON
(GSK, Tres Cantos (Madrid), Spain)
- 15:10 Identification, Optimization and Validation of a New Triaromatic Pleuromutilin Antibiotic Subclass (LE047)**
Mr Christoffer HEIDTMANN
(UNIVERSITY OF SOUTHERN DENMARK, Odense M, Denmark)

Session Session 13 'Technologies'

Reality Check "AI in Drug Design" – State of the Art or Fiction - an EFMC² session

- 13:45 Session Chairs**
Dr Werngard CZECHTIZKY (ASTRAZENECA, Mölndal, Sweden)
Dr Nadine SCHNEIDER (NOVARTIS, Basel, Switzerland)
- 13:50 AI in Drug Discovery – Hype or Reality? (LE048)**
Prof. Alexander HILLISCH
(UCB, Monheim am Rhein, Germany)
- 14:30 AI-Generated Protein Function Prediction with Therapeutic Applications (LE049)**
Dr Lucy COLWELL
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)
- 14:50 Accelerating Drug Design with AI – Reality or Hype? (LE050)**
Dr Eva NITTINGER
(ASTRAZENECA, Stockholm County, Sweden)
- 15:10 Recursion's Map-Based Drug Discovery Approach: from Project Ideation to Lead Optimization (LE051)**
Ms Lourdes RUEDA
(RECURSION, Salt Lake City, United States)
- 15:30 Exhibition & Coffee**

Session Session 14

First Time Disclosures - Part II

- 16:00 Chair**
Dr Doris RIETHER
(BOEHRINGER INGELHEIM, Biberach an der Riss, Germany)
- 16:00 Discovery of Clinical Candidate GSK484: a Novel "Irresistible" Chemical Class for the Treatment of Malaria (LE052)**
Dr Jorge FERNANDEZ
(GSK, Tres Cantos, Spain)
- 16:30 Discovery of NVP-DFF332 as an Inhibitor of the Transcription Factor Hypoxia-Inducible Factor-2ALPHA (HIF-2?) (LE053)**
Dr Robin FAIRHURST
(NOVARTIS, Basel, Switzerland)
- 17:00 First-time Disclosure of Clinical Candidate CHF-6523, an Inhaled Selective PI3K? Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (LE054)**

Programme

Dr Paolo BRUNO
(CHIESI FARMACEUTICI SPA, PARMA, Italy)

17:30 Inhibition of the NLRP3 Inflammasome is a Promising Concept to Treat a Variety of Inflammatory Diseases (LE055)

Dr Anders JOHANSSON
(ASTRAZENECA, Molndal, Sweden)

18:00 Poster Session 2 & Networking

19:30 End of the Day

Programme

Wednesday September 4, 2024

- 08:30 IUPAC-Richter Prize in Medicinal Chemistry 2024**
Induced Proximity: Exploring New Therapeutic Modalities (PR002)
 Prof. Craig CREWS
 (YALE UNIVERSITY, New Haven, United States)
- 09:10 EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry**
Ceremony & Lectures
- Chair**
 Dr Luc VAN HIJFTE
 (SYMERES, Nijmegen, The Netherlands)
- 09:10 EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN ACADEMIA**
Title to be Announced (PR003)
 Prof. Rebecca BULLER
 (ZHAW SCHOOL OF LIFE SCIENCES AND FACILITY MANAGEMENT, Wädenswil, Switzerland)
- 09:30 EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN INDUSTRY**
DNA-Encoded Chemical Libraries for the Discovery of Highly Potent Tumor-Targeting Ligands and for the Development of Anti-Cancer Small Molecule Therapeutics (PR004)
 Dr Samuele CAZZAMALLI
 (PHILOCHEM AG, Otelfingen, Switzerland)
- 09:50 Exhibition & Coffee**

Session *Session 15 'Chemical Biology'*

Bio-orthogonal Synthetic Chemistry / AFMC Session

- 10:20 Session Chairs**
 Prof. Youngjoo BYUN (KOREA UNIVERSITY, Sejong, Korea, South)
 Prof. Sun-Joon MIN (HANYANG UNIVERSITY, Gyeonggi-do, Korea, South)
- 10:25 Development of Chemical Probes for Biomedical Application via Bioorthogonal Reactions (LE056)**
 Prof. Sun-Joon MIN
 (HANYANG UNIVERSITY, Gyeonggi-do, Korea, South)
- 11:05 Minimalist Tag Approach for Chemoproteomic Target Deconvolution (LE057)**
 Prof. Jun-Seok LEE
 (KOREA UNIVERSITY COLLEGE OF MEDICINE, Seoul, Korea, South)
- 11:25 The Development of Molecular Imaging Agents for Prostate Cancer Diagnosis (LE058)**
 Prof. Xing YANG
 (PEKING UNIVERSITY FIRST HOSPITAL, Beijing, China)
- 11:45 Novel Synthetic Approaches for the Next-Generation Therapeutics (LE059)**
 Dr Sona KRAJCOVICOVA
 (UNIVERSITY OF CAMBRIDGE/PALACKY UNIVERSITY OLOMOUC, Cambridge, United Kingdom)

Session *Session 16 'Drug Discovery Projects'*

Highlights in Medicinal Chemistry

- 10:20 Session Chair**
 Dr Maria DUCA
 (UNIVERSITY OF CÔTE D'AZUR, Nice, France)
- 10:25 Nanomedicine for the Treatment of Pediatric Cancer (LE060)**
 Prof. Maria BLANCO-PRIETO
 (UNIVERSITY OF NAVARRA)

Programme

- 11:05 Discovery of a Novel SRF-Pathway Inhibitor for the Treatment of Pulmonary Fibrosis (LE061)**
Prof. Bernard FLYNN
(MONASH UNIVERSITY, Parkville, Australia)
- 11:25 The Discovery of I-1000233, a Potent Brain Permeable and Orally Bioavailable SHP2 Allosteric Inhibitor (LE062)**
Dr Alessia PETROCCHI
(IRBM SPA, Pomezia, Italy)
- 11:45 Accelerated in Silico Discovery of SGR-1505: a Potent Malt1 Allosteric Inhibitor for the Treatment of Mature B-cell Malignancies (LE063)**
Dr Michael TRZOSS
(SCHRODINGER, INC, San Diego, United States)

Session *Session 17 'Technologies'*

New Technologies for the Discovery of Protein Degraders / CPA Session

- 10:20 Session Chair**
Prof. Ke DING
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, CHINESE ACADEMY OF SCIENCES, Shanghai, China)
- 10:25 Targeted Protein Degradation Technology and Applications (LE064)**
Prof. Yu RAO
(TSINGHUA UNIVERSITY, Beijing, China)
- 11:05 Targeting Pathogenic Targets of Neurodegenerative Diseases through Autophagy-Lysosome Pathway (LE065)**
Prof. Yu DING
(FUDAN UNIVERSITY, Shanghai, China)
- 11:25 Molecular Glue Drug Development, from Serendipity to Rational Design (LE066)**
Dr Xiangbing QI
(TSINGHUA UNIVERSITY | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCE, Beijing, China)
- 11:45 Towards a Rationalized Screening Platform for Molecular Degradation Discovery (LE067)**
Dr Johanna HUCHTING
(FRAUNHOFER INSTITUTE FOR TRANSLATIONAL MEDICINE AND PHARMACOLOGY, Hamburg, Germany)
- 12:05 Exhibition & Lunch**
Optional Company workshops

Session *Session 18 'Chemical Biology'*

Early Career Women in Medicinal Chemistry & Chemical Biology

- 13:15 Session Chairs**
Dr Maria-Jesus BLANCO (ATAVISTIK BIO, Cambridge, MA, United States)
Prof. Maria Laura BOLOGNESI (UNIVERSITY OF BOLOGNA, Bologna, Italy)
- 13:20 Medicinal Chemistry and the United Development Goals: a Personal Adventure (LE068)**
Prof. Maria Laura BOLOGNESI
(UNIVERSITY OF BOLOGNA, Bologna, Italy)
- 14:00 MAGE-C2 and -A3: unraveling Novel Ligands for Targeted Cancer Therapy (LE069)**
Dr Laura SANTOS
(YALE UNIVERSITY, New Haven, United States)
- 14:20 From Benzoylpiperidine to Benzylpiperazine-Based Reversible MAGL Inhibitors: a Ten-Year Med Chem Story (LE070)**
Prof. Carlotta GRANCHI
(UNIVERSITY OF PISA, Pisa, Italy)
- 14:40 Revolutionizing Cancer Treatment: a Game-Changing Technology for Immune Checkpoints Targeting and PROTACS Development (LE071)**
Dr Maria MAJELLARO
(CELTARYS RESEARCH, Santiago de Compostela, Spain)

Programme

Session *Session 19 'Drug Discovery Projects'*

Advances in Immuno-oncology Therapy with Small Molecule Inhibitors

- 13:15 Session Chair**
Dr Murali RAMACHANDRA
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India)
- 13:20 Distinctive Roles for Small Molecule Inhibitors of Immune Checkpoint Proteins (LE072)**
Dr Murali RAMACHANDRA
(AURIGENE DISCOVERY TECHNOLOGIES LTD, Bangalore, India)
- 14:00 Targeted Protein Upregulation Potentiates STING Agonist Immunotherapy (LE073)**
Prof. Seung Bum PARK
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South)
- 14:20 Development of Novel PD-L1 and Epigenetic-Target Based Dual Inhibitors as a New Frontier in Polypharmacology Driven Anticancer Therapy (LE074)**
Ms Alessia RAUCCI
(SAPIENZA UNIVERSITY OF ROME, Rome, Italy)
- 14:40 Arginase 1/2 Inhibitor OATD-02: from Discovery to Clinical Trials in Cancer Immunotherapy (LE075)**
Dr Roman BLASZCZYK
(MOLECURE SA, Warsaw, Poland)

Session *Session 20 'Technologies'*

Impact of Cryo-EM in Drug Discovery

- 13:15 Session Chair**
Dr Herbert NAR
(BOEHRINGER INGELHEIM, Biberach, Germany)
- 13:20 Title to be Announced (LE076)**
Dr Pamela WILLIAMS
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)
- 14:00 Cryo-EM enables Structure-Based Drug Design for Membrane Protein Targets (LE077)**
Dr Katharina DÜRR
(OMASS THERAPEUTICS, Oxford, United Kingdom)
- 14:20 Identification and Optimization of Novel GPR126 Positive Allosteric Modulators: Utilizing Cryo-Em for Guided Optimization by Targeting Lipophilic Pockets and Reducing PAMs' Lipophilicity (LE078)**
Dr Stefanie FLOHR
(NOVARTIS, Basel, Switzerland)
- 14:40 Discovery of Hedgehog Acyltransferase (HHAT) Inhibitors for Treatment of Cancer (LE079)**
Dr Efthymios S. GAVRIIL
(IMPERIAL COLLEGE LONDON, London, United Kingdom)
- 15:00 End of the Day**
- 15:45 Excursions**
- 20:00 Banquet**

Programme

Thursday September 5, 2024

Session *Session 21 'Chemical Biology'*

Highlights in Chemical Biology / ICBS Session

Session Chair

Prof. Zaneta NIKOLOVSKA-COLESKA
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

08:35 Targeting the Longevity Regulator PAPP-A with Small Molecule Inhibitors (LE080)

Prof. Zaneta NIKOLOVSKA-COLESKA
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

08:55 Identification of panKRAS Inhibitors BI-2865 and BI-2493 (LE081)

Dr Joachim BROECKER
(BOEHRINGER INGELHEIM RCV GMBH & CO KG, Vienna, Austria)

09:15 From GHB to First-in-Class CaM Kinase Modulators (LE082)

Prof. Bente FRØLUND
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

09:35 Potent, Selective and Bioavailable Covalent Inhibitors of CDK7 (LE083)

Dr Ian STANSFIELD
(JOHNSON & JOHNSON INNOVATIVE MEDICINE, Beers, France)

09:55 Protein Degradation Targeted by Selective ER Translocation Inhibitors; PD-L1 Down-Modulators as Anticancer Lead Compounds (LE084)

Prof. Thomas BELL
(UNIVERSITY OF NEVADA, Reno, United States)

Session *Session 22 'Drug Discovery Projects'*

Chemical Strategies to Modulate Neuroinflammation / ACSMEDI Session

08:30 Session Chair

Prof. Nadia GERMAN
(TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER, Texas, United States)

08:35 Targeting Neuroinflammation for the Treatment of Neurodegenerative Diseases (LE085)

Dr Markus P. KUMMER
(ABBVIE, Ludwigshafen, Germany)

09:15 KOR Agonists Reduce Neuroinflammation and Promote Remyelination in Preclinical Models of Multiple Sclerosis (LE086)

Prof. Thomas PRISINZANO
(UNIVERSITY OF KENTUCKY, Lexington, United States)

09:35 New Multitarget Agents for the Treatment of Demyelinating Diseases: A2A and A2B Adenosine Receptor Antagonists Hybridized with Antioxidants (LE087)

Ms Sara CALENDRA
(UNIVERSITÀ DEGLI STUDI DI FIRENZE, Sesto Fiorentino, Italy)

09:55 Discovery of BIO-8169, a Highly Potent, Selective, and Brain Penetrant IRAK4 Inhibitor for the Treatment of Neuroinflammation (LE088)

Dr Magnus PFAFFENBACH
(BIOGEN, Lexington, United States)

Session *Session 23 'Technologies'*

Sustainability – Green Chemistry

08:30 Session Chair

Dr Álvaro ENRÍQUEZ GARCÍA
(ELI LILLY AND COMPANY, Madrid, Spain)

08:35 Enabling Technologies Applied to Accelerating Oncology Projects in a Sustainable Manner (LE089)

Dr Paul RICHARDSON
(PFIZER, San Diego, United States)

09:15 Sustainability and Green Chemistry Considerations in Medicinal Chemistry (LE090)

Programme

Prof. Magnus J. JOHANSSON
(ASTRAZENECA, Mölndal, Sweden)

09:35 Upcycled Nano-Sunscreen UV Filters from Agro-Food Industry by-Products: a Safe, Sustainable, and Effective by Design (SSEDD) Approach for Surface Modification (LE091)

Prof. Stefano MANFREDINI
(UNIVERSITÀ DI FERRARA, Ferrara, Italy)

09:55 Automated and Miniaturized Chemistry (LE092)

Dr Shabnam SHAABANI
(BAYER AG, Berlin, Germany)

10:15 Exhibition & Coffee

Session *Session 24 'Chemical Biology'*

Solute Carrier Protein (SLC) Transporters as Targets for Drug Discovery

10:45 Session Chair

Dr Andreas GOLLNER
(SOLGATE, Klosterneuburg, Austria)

10:50 Discovering The Next SLC Drugs (LE093)

Dr Andreas GOLLNER
(SOLGATE, Klosterneuburg, Austria)

11:30 Discovery, Preclinical, and Clinical Development of a Selective NKCC1 Inhibitor Drug Candidate for the Treatment of Core Symptoms of Brain Disorders with Defective NKCC1/KCC2 Ratio (LE094)

Dr Marco BORGOGNO
(IAMA THERAPEUTICS SRL, Genoa, Italy)

11:50 Title to be Announced (LE095)

Prof. Klaus T. WANNER
(LUDWIG - MAXIMILIANS-UNIVERSITÄT MÜNCHEN, Munich, Germany)

12:10 Optimization of a Pyridylpiperazine Series as a Novel Class of Efflux Pump Inhibitors in E. Coli to Fight Antimicrobial Resistance (LE096)

Dr Nina COMPAGNE
(UNIVERSITY OF LILLE, Lille, France)

Session *Session 25 'Drug Discovery Projects'*

Late Breaking News / Recent Developments

10:45 Session Chair

Dr Malin LEMURELL
(ASTRAZENECA, Gothenburg, Sweden)

10:50 Isocyanide: the Game-Changer in Medicinal Chemistry (LE097)

Ms Francesca BRUNELLI
(UNIVERSITY OF EASTERN PIEDMONT, Novara, Italy)

11:10 Efficient Discovery of Precision Allosteric Modulators by Applying an Unbiased Platform Approach (LE098)

Dr Maria-Jesus BLANCO
(ATAVISTIK BIO, Cambridge, MA, United States)

11:30 The Discovery and Development of DFV890, a Clinical Phase Inhibitor of the NLRP3 Inflammasome (LE099)

Dr Angela MACKAY
(NOVARTIS PHARMA AG, Basel, Switzerland)

11:50 Discovery of Muvalaplin: the First Oral Molecule Inhibitor of Lp(a) Formation in Clinical Trials (LE100)

Dr Nuria DIAZ
(ELI LILLY, Alcobendas, Spain)

12:10 Discovery of Highly Selective SYK Inhibitors BI 894416 and BI 1342561 to Treat Severe Asthma (LE101)

Dr Matthias HOFFMANN
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

Programme

Session *Session 26 'Technologies'*

New Technologies for Drug Delivery

10:45 Session Chair

Prof. Francesco PERI
(UNIVERSITY OF MILANO-BICOCCA, Milano, Italy)

10:50 Supramolecular Drugs Design (LE102)

Dr Giuseppe BATTAGLIA
(INSTITUT DE BIOENGINYERIA DE CATALUNYA (IBEC), Barcelona, Spain)

11:30 Considerations for Stabilising and Administering Vaccines in Solid Dosage Forms (LE103)

Dr Anne MOORE
(UNIVERSITY COLLEGE CORK, Cork, Ireland)

11:50 Exploiting yhe Synergy between Immuno-Glyco-Compounds and Nanoplatfroms Based on Metal-Organic Networks against Diabetic Retinopathy (LE104)

Dr Elena M SÁNCHEZ-FERNÁNDEZ
(UNIVERSITY OF SEVILLE, Seville, Spain)

12:10 MCR-Based Lipidoids (LE105)

Ms Paraskevi Kleio ANASTASIOU
(UNIVERSITY OF CRETE, Heraklion, Greece)

Chair

Dr Karin BRINER
(GENENTECH, South San Francisco, United States)

12:30 Closing Lecture

A Career Doing STUFF (PL003)

Dr Mike HANN
(GSK MEDICINES RESEARCH CENTRE, Stevenage, United Kingdom)

13:10 Closing Remarks, Poster Prizes & Welcome to EFMC-ISMIC 2026